Their findings suggest a novelty for the cannabinoids in which KRAS, an undruggable target expressed in many lethal cancers can be supressed through targeting PAK1 and the suppression of PDL-1 could be enhanced for immune checkpoint blockade therapy in pancreatic cancers (Yang et al. 2020). Here, KRAS is linked to familial pancreatic carcinoma.